194 related articles for article (PubMed ID: 30227885)
1. Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis.
Szeremeta A; Jura-Półtorak A; Koźma EM; Głowacki A; Kucharz EJ; Kopeć-Mędrek M; Olczyk K
Arthritis Res Ther; 2018 Sep; 20(1):211. PubMed ID: 30227885
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
3. Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis.
Adami G; Orsolini G; Adami S; Viapiana O; Idolazzi L; Gatti D; Rossini M
Calcif Tissue Int; 2016 Oct; 99(4):360-4. PubMed ID: 27307275
[TBL] [Abstract][Full Text] [Related]
4. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
6. [TNF inhibitors].
Kameda H
Nihon Rinsho; 2016 Jun; 74(6):957-62. PubMed ID: 27311185
[TBL] [Abstract][Full Text] [Related]
7. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
8. Alterations of plasma glycosaminoglycan profile in patients with rheumatoid arthritis in relation to disease activity.
Jura-Półtorak A; Komosinska-Vassev K; Kotulska A; Kucharz EJ; Klimek K; Kopec-Medrek M; Olczyk K
Clin Chim Acta; 2014 Jun; 433():20-7. PubMed ID: 24607326
[TBL] [Abstract][Full Text] [Related]
9. [MTX].
Kaneko Y
Nihon Rinsho; 2016 Jun; 74(6):944-7. PubMed ID: 27311183
[TBL] [Abstract][Full Text] [Related]
10. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
11. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
12. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The best practice for TNF inhibitors.].
Kameda H
Clin Calcium; 2018; 28(5):655-660. PubMed ID: 29731461
[TBL] [Abstract][Full Text] [Related]
15. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.
Alivernini S; Peluso G; Fedele AL; Tolusso B; Gremese E; Ferraccioli G
Arthritis Res Ther; 2016 Feb; 18():39. PubMed ID: 26842890
[TBL] [Abstract][Full Text] [Related]
16. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
Bergman M; De G; Ganguli A; Signorovitch J; Bao Y
J Med Econ; 2015 Jan; 18(1):37-44. PubMed ID: 24841451
[TBL] [Abstract][Full Text] [Related]
17. Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF-α therapy.
Kristensen AM; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Höllsberg P; Deleuran B; Hvid M
Cytokine; 2017 Aug; 96():1-7. PubMed ID: 28267648
[TBL] [Abstract][Full Text] [Related]
18. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
Liu Y; Fan W; Chen H; Yu MX
Asian Pac J Cancer Prev; 2014; 15(8):3403-10. PubMed ID: 24870729
[TBL] [Abstract][Full Text] [Related]
19. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
Murdaca G; Spanò F; Puppo F
Expert Opin Drug Saf; 2013 Nov; 12(6):801-4. PubMed ID: 23889669
[TBL] [Abstract][Full Text] [Related]
20. Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.
Sfriso P; Caso F; Filardo GS; Botsios C; Costa L; Scarpa R; Todesco S; Spinella P; Oliviero F; Punzi L
Clin Rheumatol; 2016 Jun; 35(6):1615-8. PubMed ID: 27048267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
